Previously, several studies were focused on the biodistribution and tumor accumulation/uptake of 89Zr-labeled compounds (e.g., [89Zr]-labeled cergutuzumab amunaleukin (CEA-IL2v) [162] and [89Zr]-GSK2849330 [145]) in patients with advanced solid tumors [160]. This evidence concerns the gene CEACAM5 and neoplasm.